Specialties

Semaglutide reduced major cardiovascular events by 26% in adults with type 2 at high cardiovascular risk.

Patients treated for cholesterol lowering appear to have extra benefits.

Research reveals important gaps in care.

In part 2 of this exclusive ADA interview, Anthony Cincotta discusses the Cycloset Safety Trial study design and findings regarding the cardiovascular safety of Cycloset.

In part 1 of this exclusive ADA interview, Anthony Cincotta discusses the mechanistic science behind the development of Cycloset, and why preclinical and clinical findings suggest the therapy may reset clock mechanisms governing postprandial glucose metabolism.

Initiation of glucagon like peptide-1 agonists may increase risk of gallbladder or bile duct disease and cholecystectomy; no increased risk associated with DPP-4 inhibitor therapy.

Study could not evaluate drug's long-term effects on diabetes prevention, length of effects

What benefits can medication provide in elderly patients with uncontrolled type 2?

I am a diabetes educator and certified foot care nurse. Through the years, I’ve learned that most topics we teach people who have diabetes are really topics every person should know about. I teach patients how to care for their feet, how to prevent foot problems, and how to treat them if they should have problems.

Can glycated albumin provide better positive predictive value than A1c in incidence of diabetic nephropathy?